Premium
CAMPATH‐1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura
Author(s) -
Lim S. H.,
Hale G.,
Marcus R. E.,
Waldmann H.,
Baglin T. P.
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb03117.x
Subject(s) - medicine , thrombocytopenic purpura , refractory (planetary science) , monoclonal antibody , immunology , monoclonal antibody therapy , antibody , immune system , monoclonal , antibody therapy , autoimmune disease , biology , astrobiology
Summary. Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Hodgkin's disease) refractory to conventional therapy were treated with an antilymphocyte monoclonal antibody directed at CDw52 (CAMPATH‐1). We observed response in four of the five evaluable patients; in three patients the response has lasted more than 4–9 months. However. response did not occur in most cases until 4–6 weeks after the commencement of the antibody therapy, suggesting that the mechanism of action is probably that of immune modulation.